Alnylam Pharmaceuticals (ALNY) News Today $235.56 -22.35 (-8.67%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by AnalystsNovember 16 at 4:23 AM | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by BrokeragesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-four ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold reNovember 16 at 4:17 AM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Rating Lowered to "Underperform" at Wolfe ResearchNovember 15 at 2:17 AM | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Drop in Short InterestNovember 14 at 3:11 AM | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 23.6% in OctoberAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 3,700,000 shares, a decline of 23.6% from the October 15th total of 4,840,000 shares. Based on an average daily volume of 812,200 shares, the days-to-cover ratio is presently 4.6 days.November 14 at 3:10 AM | marketbeat.comAlnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)November 13 at 3:54 AM | benzinga.comBaillie Gifford & Co. Has $1.34 Billion Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Baillie Gifford & Co. trimmed its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,887,000 shares of the biopharNovember 12, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Underperform at Wolfe ResearchWolfe Research downgraded Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday.November 12, 2024 | marketbeat.comLos Angeles Capital Management LLC Buys 135,829 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Los Angeles Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11,433.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 137,017 shares of the biNovember 11, 2024 | marketbeat.comPTC Therapeutics (PTCT) Receives a Hold from BarclaysNovember 11, 2024 | markets.businessinsider.comNew York State Teachers Retirement System Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)New York State Teachers Retirement System acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,283 shares of the biopharmaceuticalNovember 10, 2024 | marketbeat.comAIA Group Ltd Purchases 8,789 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)AIA Group Ltd boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 45.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,217 shares of the biopharmaceutical company's stNovember 8, 2024 | marketbeat.comRFK Jr. could play a big role under Trump—and Big Pharma is sounding the alarm: ‘We need somebody grounded by science and evidence, not somebody who rejects it’November 8, 2024 | msn.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of Alaska Department of RevenueState of Alaska Department of Revenue reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 52.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,030 shares of the biopharmaceutical company's stoNovember 8, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Buy" Rating from HC WainwrightNovember 8, 2024 | americanbankingnews.comWhat Mass. life science leaders expect under Donald TrumpNovember 7, 2024 | bizjournals.comHC Wainwright Has Bullish Estimate for ALNY FY2024 EarningsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a research report issued on Monday, November 4th. HC Wainwright analyst P. Trucchio now anticipates thaNovember 7, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Robeco Institutional Asset Management B.V. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 48.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor oNovember 7, 2024 | marketbeat.comA Peek at Catalyst Pharmaceuticals's Future EarningsNovember 6, 2024 | benzinga.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Boosted by Asset Management One Co. Ltd.Asset Management One Co. Ltd. raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,953 shares of the biopharmNovember 6, 2024 | marketbeat.comVan ECK Associates Corp Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Van ECK Associates Corp reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,399 shares of the biopharmaceutical company's stock aNovember 6, 2024 | marketbeat.comBarclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)November 5, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by New York State Common Retirement FundNew York State Common Retirement Fund trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 98.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,228 shares of the biopharmaceutical comNovember 5, 2024 | marketbeat.comAlnylam to Webcast Presentations at Upcoming November Investor ConferencesNovember 4, 2024 | finance.yahoo.comAlnylam Pharma: Strategic Growth and Market Dominance PotentialNovember 4, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday.November 4, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Wealth Enhancement Advisory Services LLCWealth Enhancement Advisory Services LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 56.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,454 shares of theNovember 4, 2024 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Announces Quarterly Earnings ResultsAlnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the business earned $1.15 earnings per share. The company's revenue for the quarter was down 33.3% compared to the same quarter last year.November 3, 2024 | marketbeat.comAlnylam Pharmaceuticals: Strong Product Performance and Strategic Positioning Underpin Buy RatingNovember 2, 2024 | markets.businessinsider.comSilvant Capital Management LLC Acquires 2,534 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Silvant Capital Management LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 18.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,195 shares of the biopharmaceutical company's stock after purchasNovember 2, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAlnylam Pharma: Strong Financial Position and Strategic Growth Support Buy RatingNovember 1, 2024 | markets.businessinsider.comAlnylam Pharma (ALNY) Receives a Hold from Wells FargoNovember 1, 2024 | markets.businessinsider.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $298.00 at Raymond JamesRaymond James upped their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a report on Friday.November 1, 2024 | marketbeat.comAlnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday.November 1, 2024 | marketbeat.comShepherd Financial Partners LLC Takes $752,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Shepherd Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,736 shares of the biophaNovember 1, 2024 | marketbeat.comAlnylam Pharmaceuticals Q3 2024 Earnings PreviewNovember 1, 2024 | msn.comAlnylam Pharmaceuticals to Suspend Further Clinical Development of Type 2 Diabetes TreatmentNovember 1, 2024 | marketwatch.comAlnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 1, 2024 | finance.yahoo.comAlnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period ActivityNovember 1, 2024 | finanznachrichten.deQ3 2024 Alnylam Pharmaceuticals Inc Earnings CallNovember 1, 2024 | finance.yahoo.comAlnylam Pharma’s Strong Financial Performance and Strategic Growth Justify Buy RatingNovember 1, 2024 | markets.businessinsider.comAlnylam's Revenues Drop Sharply in Q3November 1, 2024 | fool.comAlnylam Pharmaceuticals Reports Mixed Quarterly EarningsNovember 1, 2024 | tipranks.comAlnylam Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 31, 2024 | seekingalpha.comCognizant signs deal to enhance Alnylam’s IT infrastructureOctober 30, 2024 | finance.yahoo.comMirae Asset Global Investments Co. Ltd. Sells 2,764 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Mirae Asset Global Investments Co. Ltd. reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 21.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,428 shares of the biopharmaceuticalOctober 30, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short InterestAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,840,000 shares, an increase of 7.3% from the September 30th total of 4,510,000 shares. Based on an average trading volume of 828,800 shares, the short-interest ratio is presently 5.8 days.October 30, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by China Universal Asset Management Co. Ltd.China Universal Asset Management Co. Ltd. raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,340 shares of the biopharmaceutical company'sOctober 29, 2024 | marketbeat.comSemanteon Capital Management LP Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Semanteon Capital Management LP acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 2,758 shares of the biopharmaceutical company's stock, valued at approximatelOctober 28, 2024 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too? Click Here For Your Free Guide ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.580.55▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼1410▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BeiGene News Royalty Pharma News Sarepta Therapeutics News Catalent News Elanco Animal Health News Vertex Pharmaceuticals News Gilead Sciences News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts